Aurinia Pharmaceuticals Inc
$ 16.07
0.06%
14 Apr - close price
- Market Cap 2,135,514,000 USD
- Current Price $ 16.07
- High / Low $ 16.54 / 16.06
- Stock P/E 7.76
- Book Value 4.39
- EPS 2.07
- Next Earning Report 2026-05-11
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.11 %
- ROE 0.60 %
- 52 Week High 16.54
- 52 Week Low 7.29
About
Aurinia Pharmaceuticals Inc., a biopharmaceutical company, develops and markets therapies to treat various diseases with unmet medical needs in Japan and China. The company is headquartered in Victoria, Canada.
Analyst Target Price
$17.00
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-03-04 | 2025-11-04 | 2025-07-31 | 2025-04-30 | 2025-02-13 | 2024-11-07 | 2024-08-01 | 2024-05-02 | 2024-02-15 | 2023-11-02 | 2023-08-03 | 2023-05-04 |
| Reported EPS | 1.53 | 0.23 | 0.16 | 0.16 | 0.01 | 0.1 | 0.01 | -0.03 | -0.19 | -0.09 | -0.08 | -0.18 |
| Estimated EPS | 0.1533 | 0.16 | 0.14 | 0.1 | -0.016 | 0.01 | 0.01 | -0.14 | -0.16 | -0.17 | -0.18 | -0.22 |
| Surprise | 1.3767 | 0.07 | 0.02 | 0.06 | 0.026 | 0.09 | 0 | 0.11 | -0.03 | 0.08 | 0.1 | 0.04 |
| Surprise Percentage | 898.0431% | 43.75% | 14.2857% | 60% | 162.5% | 900% | 0% | 78.5714% | -18.75% | 47.0588% | 55.5556% | 18.1818% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-11 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | 0.18 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: AUPH
2026-04-14 12:58:00
Quantitative Research Desk reports that Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) is experiencing volatility, with trading systems reacting to near-term neutral sentiment amidst mid and long-term strength. The analysis highlights an exceptional risk-reward short setup and provides institutional trading strategies tailored with distinct risk profiles and holding periods, including position trading, momentum breakout, and risk hedging strategies.
2026-04-12 11:39:54
Aurinia Pharmaceuticals Inc. announced the results of its annual general meeting held on June 21, 2018. All eight incumbent directors were re-elected with overwhelming support, and other proposals, including the appointment of auditors, were also approved. The company is clinical stage and focuses on developing therapies for diseases like lupus nephritis, FSGS, and dry eye syndrome, primarily with its investigational drug, voclosporin.
2026-04-09 07:09:45
Aurinia Pharmaceuticals is acquiring Kezar Life Sciences to expand its autoimmune disease portfolio, specifically adding the clinical candidate zetomipzomib. This acquisition aims to diversify Aurinia's revenue base beyond its single commercial product and build a broader autoimmune franchise, though it introduces execution risks related to integration and increased R&D spending. Investors will be watching how Aurinia manages the integration, updates development plans, and potentially adjusts its financial guidance.
2026-04-08 18:09:29
This article provides an earnings analysis and prediction for AUPH (Aurinia Pharmaceuticals Inc.), detailing past quarterly results and future forecasts. It highlights analyst estimates for upcoming quarters, emphasizing the relationship between earnings forecast revisions and stock price movements. The report also includes historical stock price reactions around earnings announcements and addresses frequently asked questions about AUPH's financial performance.
2026-04-06 21:11:12
This document is a transcript of the Q3 2025 earnings call for Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH). It provides a detailed record of the discussions held during the call, including financial results, operational updates, and potentially questions and answers with analysts.
2026-04-06 10:09:29
Aurinia Pharmaceuticals (AUPH) has undergone a significant leadership change, appointing Kevin Tang as CEO, Michael Hearne as CFO, and Ryan Cole as COO, with several new executives tied to Tang Capital Management. Despite a strong one-year return of nearly 100%, the stock's current price of $15.61 suggests it is undervalued, with a fair value estimate of $17.00. This valuation is supported by operational efficiency, share repurchases, and strong cash flow, though risks like patent disputes and pipeline execution remain.
